Skip to main content

People In The News: Oct 31, 2014

NEW YORK (GenomeWeb) – Former Life Technologies CEO and Chairman Greg Lucier has joined the board of directors at Invuity, a medical device company based in San Francisco. Prior to Life Tech, Lucier was chairman and CEO of Invitorgen, which merged with Applied Biosystems in 2008 to form Life Technologies. He previously held senior management positions at General Electric including CEO and president of Medical Systems Information Technologies for GE Healthcare. Lucier holds an MBA from Harvard Business School and a BS in industrial engineering from Pennsylvania State University.


Theranostics Health has appointed Luis Gutierrez president and CEO. Former CEO Glenn Hoke will remain with the company as executive vice president and COO.

Gutierrez was previously executive vice president and COO of Aptiv Solutions. Before that he was president of Covance's commercialization services division. He has also held management roles at Merck and MedAssurant.


Nabsys said that Anthony Shuber has joined the company as VP and chief scientific officer. He joins the firm from Ignyta, an oncology precision medicine firm, where he served as chief technology officer. Prior to joining Ignyta, Shuber was co-founder and CTO of Predictive Biosciences, and scientific co-founder of Exact Sciences. He also previously worked for Genzyme Genetics/Integrated Genetics and Genetics Institute.


Cepheid has promoted Warren Kocmond to the post of executive VP and COO from his previous position as EVP of global operations. The firm also promoted Peter Farrell to EVP of worldwide commercial operations from his previous post of EVP of international commercial operations. With the promotion, Farrell assumes responsibility for North American Commercial Operations, which were previously overseen by James Post, who has left the firm.


Safeguard Scientifics has appointed Mara Aspinall to its board of directors. Aspinall formerly served as president and CEO of Ventana Medical Systems and global head of Roche Tissue Diagnostics. Prior to that she had founded and served as CEO of On-Q-ity, and she also previously was president of Genzyme Genetics and president of Genzyme Pharmaceuticals.


Synthetic Genomics has appointed Oliver Fetzer as the company's new CEO, succeeding Co-founder J. Craig Venter, who will remain actively involved in SGI as executive chairman and co-chief scientist. Fetzer, who most recently served as president and CEO of Cerulean Pharma, will also be a member of SGI's board of directors. He also previously held management positions at Cubist Pharmaceuticals including senior VP of corporate development and R&D; senior VP of corporate development and chief business officer; and senior VP of business development.


Vermillion has appointed Valerie Palmieri to the newly created position of COO.

Previously, Palmieri was president of Momentum Consulting, through which she has served as a strategic advisor to Vermillion for the past six months, helping the company launch Aspira Labs, its CLIA-certified facility. She also previously served as CEO of two healthcare startups and was national vice president of anatomic pathology operations at LabCorp/Dianon.


Lucigen this week named Ralph Kauten as CEO. Kauten has been a member of Lucigen's board for the past 10 years and has served as chairman for the last four. Kauten was previously involved in the start up and management of life science companies Promega, PanVera (acquired by Aurora Biosciences) and Mirus Bio (acquired by Roche Pharmaceuticals).

David Mead, who founded Lucigen and has served as CEO from the company's inception in 1998, will remain with the company as CSO.


Cambridge Genetix appointed Fedja Bobanovic as CEO. Bobanovic was a vice president and general manager at AB Sciex, a Danaher company. Before that, he was at PerkinElmer as GM of North Europe, South Asia, the Middle East, and South Africa.

Also, Somu Subramanian has joined Cambridge's board. He is a founding member of New Science Ventures.


Promoted? Changing jobs? GenomeWeb wants to know. [email protected] to appear in People In The News, a weekly roundup of industry comings and goings.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.